Jefferies Financial Group Begins Coverage on Tempus AI (NASDAQ:TEM)
by Jessica Moore · The Cerbat GemEquities researchers at Jefferies Financial Group initiated coverage on shares of Tempus AI (NASDAQ:TEM – Get Free Report) in a note issued to investors on Monday,Benzinga reports. The firm set an “underperform” rating and a $35.00 price target on the stock. Jefferies Financial Group’s price objective points to a potential downside of 18.49% from the stock’s current price.
Several other brokerages also recently weighed in on TEM. Stifel Nicolaus set a $60.00 price target on Tempus AI in a report on Wednesday, February 25th. Mizuho initiated coverage on Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective for the company. Morgan Stanley lowered their price objective on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, HC Wainwright upped their price objective on Tempus AI from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $73.00.
Tempus AI Price Performance
Shares of NASDAQ TEM opened at $42.94 on Monday. The stock’s 50-day moving average is $51.10 and its two-hundred day moving average is $66.77. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. Tempus AI has a 1-year low of $38.79 and a 1-year high of $104.32. The company has a market cap of $7.68 billion, a price-to-earnings ratio of -30.45 and a beta of 4.90.
Insiders Place Their Bets
In other news, EVP Andrew Polovin sold 10,949 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. The trade was a 7.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the business’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $46.38, for a total value of $7,710,675.00. Following the completion of the sale, the chief executive officer directly owned 8,875,033 shares of the company’s stock, valued at $411,624,030.54. The trade was a 1.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 563,841 shares of company stock worth $32,258,311. Corporate insiders own 26.27% of the company’s stock.
Institutional Trading of Tempus AI
Several institutional investors and hedge funds have recently made changes to their positions in TEM. Cranbrook Wealth Management LLC purchased a new stake in shares of Tempus AI in the 3rd quarter valued at about $25,000. JPL Wealth Management LLC acquired a new position in Tempus AI in the 3rd quarter valued at about $26,000. Los Angeles Capital Management LLC acquired a new position in Tempus AI in the 4th quarter valued at about $27,000. GAMMA Investing LLC acquired a new position in Tempus AI in the 3rd quarter valued at about $28,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Tempus AI in the 3rd quarter valued at about $38,000. 24.22% of the stock is owned by hedge funds and other institutional investors.
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.